While CD73-targeting antibody therapy can potentiate the anti-tumor activity of NK cells via ADCC, a recent study showed that blockade of CD73 with anti-CD73 clone 7G2 in conjunction with anti-CD39 clone A1 enhanced NK cell cytotoxicity in vitro via a mechanism that includes adenosinergic metabolism and is independent of ADCC (104). The gene discussed is NT5E; the disease is neoplasm.